Dodd S, Mitchell PB, Bauer M, Yatham L, Young AH, Kennedy SH, Williams L, Suppes T, Lopez Jaramillo C, Trivedi MH, Fava M, Rush AJ, McIntyre RS, Thase ME, Lam RW, Severus E, Kasper S, Berk M. (2017). Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. The World Journal of Biological Psychiatry.
https://doi.org/10.1080/15622975.2017.1379609.
When this article was originally published online, there was an error. The paper cited a review paper that stated that “both venlafaxine and desvenlafaxine may cause raised blood pressure and possibly QTc prolongation in overdose”, incorrectly suggesting that venlafaxine and desvenlafaxine share the same cardiovascular safety profile. Desvenlafaxine has not been associated with QTc prolongation in overdose.
A correction has been made to section 5.4.3. Cardiovascular disease. Desvenlafaxine has been deleted from this paragraph so that it now states “venlafaxine may cause raised blood pressure and possibly QTc prolongation in overdose”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.